[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344683-105":59,"doc-detail-344683-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","venous-thromboembolism-in-women-with-breast-and-gynaecological-cancers-what-do-we-know-and-what-should-we-do","Venous Thromboembolism in Women with Breast and Gynaecological Cancers - What Do We Know and What Should We Do","","Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology. Female-specific cancers—including breast, ovarian, endometrial, and cervical malignancies—show distinct thrombotic profiles shaped by hormonal mechanisms, anatomic characteristics, and treatment approaches. This narrative review synthesizes epidemiological evidence, mechanistic pathways, and clinical trial data to define CAT risk across these cancers, highlighting hormonal exposures, tumor histology, inflammation, tissue factor expression, and therapies such as surgery, chemotherapy, endocrine therapy, targeted agents, and immunotherapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/venous-thromboembolism-in-women-with-breast-and-gynaecological-cancers-what-do-we-know-and-what-should-we-do/344683/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/venous-thromboembolism-in-women-with-breast-and-gynaecological-cancers-what-do-we-know-and-what-should-we-do/344683.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is cancer-associated thrombosis (CAT) and why is it important in women with cancer?","Question",{"text":113,"@type":114},"CAT is venous thromboembolism occurring in the context of cancer. It is linked to poor prognosis and reduced overall survival, making it a leading cause of death in malignancy patients.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What factors influence CAT risk in female-specific cancers?",{"text":118,"@type":114},"Key modulators include hormonal exposures, tumor histology, inflammatory signaling, tissue factor expression, and cancer treatments such as surgery, chemotherapy, endocrine therapy, targeted agents, and immunotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"Why are current CAT risk prediction models inadequate for women with breast and gynecological cancers?",{"text":122,"@type":114},"Current models do not sufficiently capture the heterogeneity of female cancers and fail to integrate bleeding risks specific to gynecologic disease and treatment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344683,1790336623,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Venous Thromboembolism in Women with Breast and Gynaecological Cancers: What Do We Know and What Should We Do?  \nClinical and Applied Thrombosis/Hemostasis Volume 32: 1-11 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10760296251415374](DOI: 10.1177/10760296251415374)[ ](DOI: 10.1177/10760296251415374)[journals.sagepub.com/home/cat](journals.sagepub.com/home/cat)  \nGeraldine Poenou, MD, PhD 1,2,3 , Pauline Corbaux, MD, PhD4,5, Sandrine Accassat, MD 1, Celine Chauleur, MD, PhD2,7, and Laurent Bertoletti, MD, PhD 1,2,3,8   \nAbstract  \nCancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology. Female-speciﬁc cancers—including breast, ovarian, endometrial, and cervical malignancies—demonstrate distinct thrombotic proﬁles inﬂuenced by hormonal mechanisms, anatomical features, and treatment strategies. This narrative review synthesizes epidemiological evidence, mechanistic pathways, and clinical trial data to characterize CAT risk across these cancer types. Key modulators of thrombosis include hormonal exposures, tumor histology, inﬂammatory signaling, tissue factor expression, and therapeutic interventions such as surgery, chemotherapy, endocrine therapy, targeted agents, and immunotherapy. Despite growing understanding, current CAT risk prediction models insufﬁciently reﬂect the heterogeneity of female cancers and fail to integrate bleeding risks speciﬁc to gynecologic disease and treatment. Optimizing CAT prevention and management will require improved risk stratiﬁcation tools, individualized thromboprophylaxis strategies, and incorporation of survivorship considerations, including fertility and contraception counseling. A multidisciplinary approach involving oncology, gynecology, and thrombosis specialists is essential to reduce the burden of CAT and improve outcomes for women with cancer.  \nKeywords  \ncancer, thrombosis, women  \nReceived: 15 May 2025; revised: 6 December 2025; accepted: 25 December 2025  \n\n| 1 Department of Vascular and Therapeutic Medicine, St-Etienne | 6Department of Vascular and Therapeutic Medicine, St-Etienne |\n| --- | --- |\n| University Hospital, Saint-Etienne, France | University Hospital, Saint-Etienne, France |\n| 2INSERM, UMR1059, Vascular Dysfunction and Haemostasis Team, | 7Department of Gynecology and Obstetrics, University Hospital Centre |\n| Jean-Monnet University, Saint-Etienne, France\u003Cbr>3INSERM, CIC-1408, Saint-Etienne University Hospital, Saint-Etienne, France | of Saint-Étienne, Saint-Étienne, France\u003Cbr>8F-CRIN INNOVTE, France |\n| 4Medical Oncology, Institut de Cancérologie et | Corresponding Author: |\n| d’ Hématologie Universitaire de Saint-Étienne (ICHUSE), | Geraldine Poenou, Department of Vascular and Therapeutic Medicine, |\n| Centre Hospitalier Unniversitaire de Saint-Etienne, Saint-Etienne, | St-Etienne University Hospital, Saint-Etienne, France; INSERM, |\n| France | UMR1059, Vascular Dysfunction and Haemostasis Team, Jean-Monnet |\n| 5EA UCBL/HCL 3788, Centre pour l’Innovation en Cancérologie de | University, SAINBIOSE Unit, Saint-Etienne, France; INSERM, CIC-1408, |\n| Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University | Saint-Etienne University Hospital, F-42055, Saint-Etienne, France. |\n| Lyon 1, Lyon, France | Email: gé[raldine.poenou@chu-st-etienne.fr](raldine.poenou@chu-st-etienne.fr) |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/l](https://creativecommons.org/l)icenses/by-nc/4.0/) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access page ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).","cbCaipBytmxUQTwX","https://ap.wps.com/l/cbCaipBytmxUQTwX","pdf",439088,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What is cancer-associated thrombosis (CAT) and why is it important in women with cancer?\",\"answer\":\"CAT is venous thromboembolism occurring in the context of cancer. It is linked to poor prognosis and reduced overall survival, making it a leading cause of death in malignancy patients.\"},{\"question\":\"What factors influence CAT risk in female-specific cancers?\",\"answer\":\"Key modulators include hormonal exposures, tumor histology, inflammatory signaling, tissue factor expression, and cancer treatments such as surgery, chemotherapy, endocrine therapy, targeted agents, and immunotherapy.\"},{\"question\":\"Why are current CAT risk prediction models inadequate for women with breast and gynecological cancers?\",\"answer\":\"Current models do not sufficiently capture the heterogeneity of female cancers and fail to integrate bleeding risks specific to gynecologic disease and treatment.\"}]","Venous Thromboembolism in Women with Breast and Gynaecological Cancers - What Do We Know and What Should We Do | PDF",1790054915,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01873557f289b6eb8a9b0a36e5afa661.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09190ba418fc9d0899fef1563b74ec0b.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f499f645300f5eb128c4df01a36cfe0c.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34debe37faea1993a768f0a996d7d6fc.webp",980,1311]